INTRODUCTION
============

Although pancreatic cancer is a relatively infrequent malignancy, it is lethal and has a high mortality rate because curative treatment of pancreatic cancer is extremely difficult \[[@b1-ce-2019-018],[@b2-ce-2019-018]\]. The age-standardized incidence and mortality rates of pancreatic cancer were 9.0 and 7.4 per 100,000 population, and it was the fourth leading cause of cancer-related death in 2013 in Japan \[[@b3-ce-2019-018]\]. Similarly, the American Cancer Society estimated that 55,440 patients would be diagnosed with pancreatic cancer and that 44,330 deaths would be caused by pancreatic cancer in 2018 \[[@b4-ce-2019-018]\]. An analysis of the 30-year cancer registry in Japan found that the overall 5-year survival rate was about 13% over the last 8 years \[[@b5-ce-2019-018]\]. However, identification of pancreatic cancers at an early stage has been reported to result in better survival rates \[[@b5-ce-2019-018]\]. According to the Japan Pancreatic Cancer Registry, the 5-year survival rates in patients with the Union for International Cancer Control Stage 0, Stage IA, and Stage IB pancreatic cancers were 85.8%, 68.7%, and 59.7%, respectively. Therefore, clinicians have been struggling to find early, small pancreatic cancers.

Similar to other epithelial neoplasms, pancreatic cancer arises from the epithelium of pancreatic ducts. Morphological changes related to pancreatic cancer begin within the pancreatic duct rather than within the pancreatic parenchyma. Imaging findings indicative of pancreatic cancer at an early stage have recently been reported \[[@b2-ce-2019-018],[@b6-ce-2019-018]-[@b8-ce-2019-018]\]. According to several reports, pancreatic cancers have been detected at an early stage based on the presence of fine, short stenosis of the main pancreatic duct (MPD) \[[@b2-ce-2019-018],[@b9-ce-2019-018],[@b10-ce-2019-018]\]. However, cases with such MPD irregularities caused by spontaneous inflammation, i.e., non-neoplastic changes, are often encountered in daily practice. The prevalence of pancreatic cancer at the stenotic site is unknown. We retrospectively evaluated the predictive reliability of MPD findings that indicate pancreatic cancer at the early stage.

MATERIALS AND METHODS
=====================

Patients
--------

We intentionally performed endoscopic retrograde pancreatography (ERP) in 689 patients from January 2008 to September 2018. From this population, we extracted data of patients who underwent ERP for examination of localized MPD stenosis that was detected during other examinations ([Fig. 1](#f1-ce-2019-018){ref-type="fig"}, [Table 1](#t1-ce-2019-018){ref-type="table"}). To evaluate only slight changes in MPD that potentially indicated a tiny neoplasm, including an intraepithelial cancer, we excluded patients with a detectable mass (detected using imaging techniques other than ERP). Patients with abnormal MPD-related findings due to definite chronic pancreatitis, intraductal papillary mucinous neoplasms, and autoimmune pancreatitis were also excluded. In addition, patients with multiple stenoses were excluded because these findings indicate chronic inflammatory changes rather than neoplasms.

The final diagnosis of the etiology of MPD stenosis was defined as being (1) malignant or benign on the basis of histological diagnosis in cases involving surgical resection, (2) malignant when an obviously malignant tumor appeared at the site during follow-up without resection, and (3) benign when the abnormality had improved or had not changed after the 5-year follow-up. When improvement or lack of change was difficult to determine, the patient was excluded. Patients who did not undergo endoscopic ultrasound (EUS), dynamic computed tomography (CT), magnetic resonance cholangiopancreatography, or ERP after the 5-year follow-up were not diagnosed with benign stenosis and were excluded from the study, even if clinical course, laboratory data, and transabdominal ultrasound (US) findings did not indicate an obvious malignancy in the pancreas.

We finally included 19 patients (mean age, 69.9±13.2 years; male, 10) who had a single, localized MPD stenosis without a detectable mass (detected using other imaging methods) in this study.

Outcome measurements
--------------------

The main outcome was the predictive reliability of MPD findings for indicating suspicious pancreatic cancer at an early stage (FiCE). The criteria for a FiCE were (1) a single, localized stenosis of MPD without a mass on US, EUS, CT, or magnetic resonance imaging (MRI), and (2) the absence of clinical evidence for other MPD etiologies, such as intraductal papillary mucinous neoplasms, autoimmune pancreatitis, definite chronic pancreatitis, pancreatic stones, previous surgical intervention, and past physical injury ([Table 1](#t1-ce-2019-018){ref-type="table"}). Localized stenosis was defined as an obvious decrease in MPD diameter, compared with the diameters of both the ampullary and tail sides of the MPD. The predictive value was estimated using the percentage of patients with pancreatic neoplasms at the stenotic site among those with FiCE.

Secondary outcome measures were detailed findings related to the MPD, prevalence of tumor invasion on histological evaluation, stage of the malignancy, and diagnostic outcomes of cytology using pancreatic juice samples obtained during ERP examination.

The degree of MPD stenosis was estimated using ERP in which the contrast agent was injected from the ampullary side of the stenosis; the degree of MPD stenosis was classified into three groups: (1) complete obstruction (contrast agent could not be injected beyond the stenosis); (2) a severe thread-like stricture (contrast agent could advance beyond the stenosis); and (3) mild stenosis with a gentle change in MPD diameter. MPD diameter at the tail side of the stenosis was classified as follows: (1) "highly dilated", diameter \>2 times the MPD diameter at the ampullary side; (2) "moderately dilated", diameter \<2 times the MPD diameter at the ampullary side; and (3) "no dilation", diameter less than that of the MPD on the ampullary side.

Pancreatic juice was obtained using a cannula for a 0.035-inch guidewire with a side hole (PR-104Q; Olympus Co., Tokyo, Japan) or a double lumen catheter for 0.035-inch and 0.025-inch guidewires (Uneven cannula; Piolax Medical Devices, Inc., Yokohama, Japan). Before aspiration of pancreatic juice, the stenotic site was rubbed with a guidewire to scratch off the epithelial cells. Lavage was performed with 40--60 mL saline while using a double lumen catheter. The obtained samples were prepared using the cell-block method and were evaluated with hematoxylin-eosin and periodic acid-Schiff/alcian blue staining; if necessary, additional immunohistochemistry, such as staining for p53, Ki67, and MUC1, was also performed. Histological diagnosis was confirmed by an expert pathologist specializing in pancreatobiliary pathology (YN) and by another experienced pathologist who worked as a consultant at our center at that time.

Cytological diagnosis was classified as positive and negative. Cells judged as being definitely cancerous, those strongly suspected of being cancerous, and those that were difficult to judge but were consistent with cancer, i.e., results corresponding to Papanicolaou Class V, IV, and IIIb, were defined as being cytologically positive, whereas the others were defined as being cytologically negative.

The presence of a pancreatic mass was evaluated using EUS, enhanced dynamic CT, and MRI if the patient did not have a contraindication to the examination. EUS was performed using radial-arrayed (GF-UM2000, GF-UE260; Olympus) or convex-arrayed (GF-UCT260; Olympus) echoendoscopes by an expert endosonographer who had performed more than 1,000 examinations or by a trainee under an expert's supervision.

Ethics
------

Written informed consent was obtained for surgery and examinations, such as enhanced CT, EUS, and ERP. This retrospective study was approved by the Institutional Review Board of Sendai City Medical Center.

RESULTS
=======

Diagnostic yield of FiCE
------------------------

Among the 19 enrolled patients with FiCE, 11 underwent surgical resection (\#1--\#11 in [Table 2](#t2-ce-2019-018){ref-type="table"}) and the other 8 were followed up without surgery (\#12--\#19).

The final diagnosis of MPD stenosis was pancreatic cancer in 9 of the 11 patients who underwent surgery ([Fig. 2](#f2-ce-2019-018){ref-type="fig"}) and a non-neoplastic change in the remaining 2 patients ([Fig. 3A](#f3-ce-2019-018){ref-type="fig"}, [B](#f3-ce-2019-018){ref-type="fig"}). Among the 9 patients who underwent surgery for malignant stenosis, 3 (\#1, \#4, and \#5) did not undergo resection immediately after ERP ([Fig. 3C--I](#f3-ce-2019-018){ref-type="fig"}). Patient \#1 underwent resection for pancreatic cancer after a 14-month interval because she had previously undergone resection for simultaneously detected lung cancer. Patients \#4 and \#5 did not undergo immediate resection owing to negative cytology results; however, they underwent surgery 42 and 5 months later, respectively, because a mass detected at the stenosis site was diagnosed as malignant via EUS-guided fine needle aspiration cytology.

In the remaining 8 patients, MPD stenosis was judged as being non-neoplastic after clinical follow-up of \>5 years (median follow-up period, 74 months; range, 62--102 months). No patients were found to have malignancies at the MPD stenosis site after clinical follow-up without resection.

Overall, MPD FiCE was finally diagnosed as a pancreatic cancer-related change in 9 patients (47%) and a non-neoplastic change in 10 patients. In other words, the predictive value of FiCE for prevalence of pancreatic cancer was 47%.

Of the 9 patients with pancreatic cancer, 3 were diagnosed with intraepithelial adenocarcinoma (high-grade pancreatic intraepithelial neoplasia \[HG-PanIN\]) and the remaining 6 with invasive ductal adenocarcinoma, based on examination of resected specimens. Mean size of the invasive region was 12.7±8.8 mm in the 6 patients with invasive cancer. The final cancer stages were as follows: 0, 3 patients; IA, 2 patients; IB, 2 patients; and IIB, 2 patients. Although no patients had distal metastases, Stage IIB cancers were accompanied by metastases to a pancreatic regional lymph node. Although EUS, dynamic CT, and MRI were performed for all enrolled patients, no masses were identified, even during retrospective review. In the 2 patients who showed invasive regions sized \>20 mm, the invasive regions were not reported to be round, dense, or well-demarcated, possibly due to the difficulty in detection during imaging examinations ([Fig. 4](#f4-ce-2019-018){ref-type="fig"}).

MPD findings
------------

MPD stenosis was located at the pancreatic head, body, and tail in 2, 6, and 1 patients with cancer and in 1, 7, and 2 patients without cancer, respectively (no statistical difference) ([Table 2](#t2-ce-2019-018){ref-type="table"}). Moreover, degree of stenosis and tail-side dilation did not differ between patients with and without cancer. Lengths of the stenosis were also similar in both groups.

Other clinical findings
-----------------------

Abdominal examinations, through which MPD findings were detected, were performed due to acute pancreatitis in 5 patients and abdominal pain in 3 patients. The remaining 11 patients, including 4 in whom abnormalities were detected via screening US, did not have any symptoms.

Serum carcinoembryonic antigen (CEA) levels were within the normal limit (\<5.0 ng/mL) in all patients except two whose CEA levels were slightly elevated due to smoking. Elevated serum carbohydrate antigen 19-9 (CA19-9) levels (normal limit, \<37.0 U/mL) were observed in two patients with invasive cancer (\#7 and \#9), but serum CA19-9 levels decreased to normal after resection.

No patients exhibited any clinical features indicative of pancreatic cancer, including anorexia, weight loss, new-onset diabetes, indigestion, and pyrexia.

Accuracy of pancreatic juice cytology
-------------------------------------

The sensitivity, specificity, and accuracy of pancreatic cytology performed on samples from 18 patients were 67%, 100%, and 83%, respectively. The sample obtained from a patient with a HG-PanIN (\#3 in [Table 2](#t2-ce-2019-018){ref-type="table"}) was not sufficient for histological evaluation. Excluding this sample, the sensitivity, specificity, and accuracy of cytology were 75%, 100%, and 88%, respectively. Two patients received false-negative diagnoses (\#4 and \#7); in these patients, the investigated cells were judged as only having mild atypia that could not be defined as malignant change. Five patients, who did not have neoplastic cells in their pancreatic juice samples (\#3, \#4, \#7, \#10, and \#11) desired and underwent surgical resection after giving full informed consent. Pancreatic juice cytology was not performed for one patient (\#12) because the procedure was ceased before obtaining sufficient pancreatic juice due to patient's non-cooperation.

Post-procedural pancreatitis with mild severity, according to Consensus Criteria \[[@b11-ce-2019-018],[@b12-ce-2019-018]\], was observed in 3 patients (16%).

Prognosis
---------

All 10 patients who underwent surgery for neoplastic stenosis were still alive during the median follow-up period of 9 months (range, 3--68 months), which lasted till the last checkup before this analysis. However, one Stage-IA cancer patient who showed an invasive region of 8 mm developed metastatic recurrence in the lung, although he has been alive for 18 months after surgery without chemotherapy (\#4 in [Tables 2](#t2-ce-2019-018){ref-type="table"}, [3](#t3-ce-2019-018){ref-type="table"}). Another patient showed metachronous pancreatic cancer in the remnant pancreatic head (\#6). This patient underwent surgical resection of the remnant pancreas for the Stage-IA cancer 39 months after the first surgery and has be alive for 17 months post-second surgery without recurrence.

The 2 patients who underwent distal pancreatectomy despite a non-neoplastic stenotic change are alive without surgery-related sequelae 280 (\#10) and 75 (\#11) days, respectively, post-surgery. All 8 patients who did not undergo surgery are alive after a median follow-up period of 74 months.

DISCUSSION
==========

Although identification of small cancers is generally associated with a better prognosis, in pancreatic cancer, the 5-year survival rate has been reported to be only around 80%, even when the tumor size is \<10 mm \[[@b5-ce-2019-018]\]. In other words, 20% of patients die even if the mass is sized \<10 mm. Therefore, pancreatic cancer with parenchymal invasion is related to mortality, even when the mass is small. This is the reason why, at present, early stage pancreatic cancer is not defined by any classification or guidelines. For ensuring the consistency of definition of early pancreatic cancer with other gastrointestinal cancers, in which early stage is defined as cancer without invasion into the muscular layer, we think that early pancreatic cancer can be defined as cancer without invasion, i.e., intraepithelial cancer.

Intraepithelial cancer in the pancreatic duct may induce intraluminal changes, such as stenosis at the lesion and dilation of the upstream duct. When a lesion develops in the MPD, it can be identified by detecting changes in the MPD via imaging examinations, even if the lesion itself cannot be visualized. Recently, detection of intraepithelial pancreatic cancer by investigation of abnormal MPD findings has been reported \[[@b2-ce-2019-018],[@b9-ce-2019-018],[@b10-ce-2019-018],[@b13-ce-2019-018],[@b14-ce-2019-018]\]. At present, such MPD findings are the sole indicator for intraepithelial pancreatic cancer.

However, non-cancer cases with such MPD findings are often encountered. The predictive accuracy or rate of negative diagnosis of such findings has not been determined. We attempted to estimate the predictive value of these MPD findings in this study. Although this study is limited by the small sample size and retrospective setting, we observed an intermediate rate of negative diagnosis.

Confirming benignity is extremely difficult when the patient is followed-up without surgical resection. In this study, the minimal time for diagnosing benignity was defined to be 5 years in which the clinical course remained consistent and MPD findings did not change on imaging examination. Although this definition is not perfect, the period could not be extended to avoid inclusion of patients who developed new tumors at the stenotic site. Benign MPD stenosis is caused by inflammation and can induce chronic inflammation; therefore, new malignancies can occur at that site. Because we cannot conduct a "perfect" study in which all patients undergo resection owing to ethical reasons, the definition used in this study is appropriate.

However, this limitation might provide misleading values in terms of cancer prevalence because we excluded patients MPD FiCE who were followed up without surgery for \<5 years. These patients were probably considered to have a benign course based on negative cytology and/or the doctor's impression. As this study may have included cases in which evident malignant changes occurred during follow-up, the stenosis in most of the aforementioned patients could be benign. Therefore, the actual prevalence rate of malignancy might be lower.

MPD findings, including severity of stenosis, length of the stenotic site, and diameter of the upstream duct, did not differ among those with and without cancer in this study. In other words, it was extremely difficult to differentiate between neoplasm and non-neoplasm based on MPD findings. Therefore, histological confirmation is important. As EUS-guided fine needle aspiration cannot be applied because of absence of a mass, pancreatic juice cytology is the sole method for obtaining samples. Although a relatively favorable diagnostic yield was obtained in this study, further improvements are necessary. Iiboshi et al. have reported the usefulness of serial pancreatic-juice aspiration cytologic examination (SPACE) using a nasopancreatic catheter that is endoscopically inserted via the papilla \[[@b9-ce-2019-018]\]. In their study, the sensitivity, specificity, and accuracy for detecting pancreatic cancer were 100%, 83%, and 95%, respectively, when pancreatic juice was intermittently sampled for an average of 5.3 times (range, 2--11 times) per person. Although SPACE appears to be the best way for sampling cells from the pancreatic duct at present \[[@b2-ce-2019-018],[@b6-ce-2019-018]-[@b8-ce-2019-018],[@b14-ce-2019-018],[@b15-ce-2019-018]\], modifications for avoiding related issues, such as adverse events, discomfort in the nose, repetitive troublesome tasks, and requirement of experienced cytopathologists, might be needed before widespread application.

Appropriate performance and timing of ERP for evaluating FiCE, which has been confirmed to be related with pancreatic cancer with approximately 50% certainty, should be discussed. ERP evaluation is of no value in patients who are ineligible for surgical pancreatectomy. Patients with advanced age or with severe comorbidities that limit their prognoses do not require definite diagnosis using ERP because detection of early-stage cancer would not determine the prognoses of these patients. ERP would also not be required in patients in whom MPD findings have not changed over a long observation period, those with a history of severe pancreatitis that might have caused MPD irregularities, and those in whom previous cytological evaluation did not reveal malignancy. Contrastingly, ERP should be considered in young people, those without previous evaluations, those with high-risk factors for cancer (such as family history of pancreatic cancer), and those without strong risk factors for post-procedural pancreatitis (such as pancreatitis history). If ERP is not performed for evaluating FiCE, the patient should be carefully observed using dynamic CT, MRI, and EUS.

This retrospective study has limitations owing to the small sample size and single-center approach. Moreover, as mentioned before, this study also involved a selection bias; surgery was immediately performed on patients who were strongly suspected of having malignancies whereas other patients were observed and excluded if the follow-up period was insufficient. The actual prevalence of pancreatic neoplasms in patients with FiCE should be confirmed using prospective studies with large study populations.

In conclusion, the cause of a single, localized MPD stenosis was pancreatic cancer in 47% of patients with no other pancreatic disease or a detectable mass. Histological confirmation via pancreatic juice cytology is necessary to avoid unnecessary pancreatic resections.
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![Study flow chart. AIP, autoimmune pancreatitis; CT, computed tomography; ERP, endoscopic retrograde pancreatography; EUS, endoscopic ultrasonography; FiCE, findings for indicating suspicious pancreatic cancer at an early stage; IPMN, intraductal papillary mucinous neoplasms; MPD, main pancreatic duct; MRI, magnetic resonance imaging.](ce-2019-018f1){#f1-ce-2019-018}

![Endoscopic retrograde pancreatography in patients diagnosed with malignant main pancreatic duct (MPD) stenosis with (findings for indicating suspicious pancreatic cancer at an early stage) without masses that are detectable via other imaging examinations. (A-I) show cases \#1--\#9 (Table 2) in a sequential order. (B, E, F) (Cases \#2, \#5, and \#6, respectively) were obtained after a catheter was advanced into the tail side of the MPD along a guidewire, although contrast was not injected into the tail side as the catheter could not be advanced beyond the stenosis. Arrowheads indicate stenosis of the MPD.](ce-2019-018f2){#f2-ce-2019-018}

![Endoscopic retrograde pancreatography and magnetic resonance cholangiopancreatography (MRCP) in patients diagnosed with benign main pancreatic duct (MPD) stenosis with (findings for indicating suspicious pancreatic cancer at an early stage) without masses that are detectable via other imaging examinations. (A-I) show Cases \#10--\#18 (Table 2) in a sequential order. Because neither contrast nor a catheter could be advanced to the tail side of the MPD in Case \#12, MRCP is additionally shown to show tail-side pancreatography (C). (B, D, J) (Cases \#11, \#13, and \#17, respectively) were obtained after a catheter was advanced into the tail side of the MPD along a guidewire, although contrast was not injected into the tail side before the catheter was advanced beyond the stenosis.](ce-2019-018f3){#f3-ce-2019-018}

![Cancer invasion, with the invasive region being 27 mm in size (Case \#9 in Table 2). (A) Mapping through divided faces; (B) Mapping through cutting lines; (C) Microscopic examination of hematoxylin-eosin-stained specimen (×10) showing a whitish, hard region, indicating that invasive cancer was not identified macroscopically on the divided faces. Microscopic evaluation shows that the invasive region (red color) was not round, dense, or well-demarcated, possibly due to the difficulty in detection during imaging examinations. The invasive region is indicated in red and the high-grade pancreatic intraepithelial neoplasia is indicated in yellow. The white box in (A) indicates the location of (C). The blue arrow indicates the main pancreatic duct near the stenosis.](ce-2019-018f4){#f4-ce-2019-018}

###### 

Criteria for Defining Main Pancreatic Duct Findings for Indicating Suspicious Pancreatic Cancer at an Early Stage in This Study

  --------------------------------------------------------------
  Inclusion criteria
   - Localized stenosis of the MPD
   - Evaluation of the MPD by an intended ERP
  Exclusion criteria
   - A mass that is detectable on other imaging examinations
   - Multiple stenosis of the MPD
   - Accompaniment of the following diseases
    Intraductal papillary mucinous neoplasms of the pancreas
    Autoimmune pancreatitis or IgG4-related disease
    Definite chronic pancreatitis, including pancreatic stones
    History of physical injury to the pancreas
   - State after surgical intervention related to the pancreas
  --------------------------------------------------------------

ERP, endoscopic retrograde pancreatography; MPD, main pancreatic duct.

###### 

Characteristics of the Patients Included in This Study

  Case   Age (yr)   Sex   Final diagnosis   Stenosis location   Reason for pancreas examination   Examination for initial detection of MPD abnormality   Acute pancreatitis history   CEA (ng/mL)   CA19-9 (U/mL)   Degree of stenosis on ERP   Length of stenosis (mm)   Dilation of the MPD in the tail side   Maximal diameter of the MPD in the tail side (mm)   Results of PJC^[a)](#tfn1-ce-2019-018){ref-type="table-fn"}^   Follow-up period without surgery (mo)
  ------ ---------- ----- ----------------- ------------------- --------------------------------- ------------------------------------------------------ ---------------------------- ------------- --------------- --------------------------- ------------------------- -------------------------------------- --------------------------------------------------- -------------------------------------------------------------- ---------------------------------------
  1      82         F     IN                Pb                  Acute pancreatitis                US                                                     \+                           3.3           5.4             Mild stenosis               10--20                    Moderate                               6                                                   4                                                              \-
  2      68         F     IN                Pb                  Abdominal pain                    CT                                                     --                           1.2           3.3             Complete obstruction        \<5                       High                                   8                                                   3b                                                             \-
  3      59         M     IN                Pb                  Abdominal pain                    MRI                                                    --                           0.8           4.2             Severe stricture            \<5                       Moderate                               2                                                   Not evaluable                                                  \-
  4      83         M     Invasive cancer   Pb                  Unknown                           MRI                                                    --                           4.7           31.6            Mild stenosis               10--20                    No                                     7                                                   2                                                              \-
  5      72         F     Invasive cancer   Ph                  Elevated serum amylase level      CT                                                     --                           2.2           \<2.0           Complete obstruction        \<5                       High                                   4                                                   3b                                                             \-
  6      65         M     Invasive cancer   Pb                  Screening                         MRI                                                    --                           1.3           7.8             Complete obstruction        5--10                     High                                   10                                                  5                                                              \-
  7      70         M     Invasive cancer   Ph                  Elevated serum CA19-9 level       CT                                                     --                           2.0           101.7           Severe stricture            5--10                     Moderate                               3                                                   2                                                              \-
  8      74         M     Invasive cancer   Pt                  Elevated serum CEA level          CT                                                     --                           10.9          6.8             Severe stricture            \>20                      Moderate                               5                                                   3b                                                             \-
  9      78         F     Invasive cancer   Ph                  Acute pancreatitis                CT                                                     \+                           3.0           600.5           Severe stricture            5--10                     High                                   10                                                  4                                                              \-
  10     87         F     No neoplasia      Pb                  Acute pancreatitis                CT                                                     \+                           2.1           5.2             Severe stricture            5--10                     Moderate                               4                                                   2                                                              \-
  11     79         F     No neoplasia      Pb                  Abnormal LFTs                     MRI                                                    --                           1.1           3.8             Severe stricture            \<5                       High                                   4                                                   2                                                              \-
  12     27         M     No neoplasia      Pb                  Acute pancreatitis                CT                                                     \+                           2.2           5.9             Complete obstruction        \<5                       High                                   10                                                  Not performed                                                  67
  13     64         F     No neoplasia      Pb                  Screening                         US                                                     --                           1.9           11.4            Severe stricture            5--10                     High                                   5                                                   1                                                              65
  14     71         M     No neoplasia      Ph                  Abdominal pain                    MRI                                                    --                           2.5           6.6             Complete obstruction        5--10                     High                                   5                                                   2                                                              81
  15     63         M     No neoplasia      Pb                  Abnormal LFTs                     MRI                                                    --                           1.7           4.3             Severe stricture            5--10                     No                                     3                                                   2                                                              102
  16     55         M     No neoplasia      Pt                  Acute pancreatitis                CT                                                     \+                           6.0           5.9             Severe stricture            5--10                     Moderate                               3                                                   2                                                              68
  17     77         F     No neoplasia      Pb                  Screening                         US                                                     --                           4.0           28.7            Mild stenosis               5--10                     No                                     3                                                   2                                                              84
  18     72         F     No neoplasia      Pt                  Screening                         CT                                                     --                           1.6           \<2.0           Complete obstruction        \<5                       Moderate                               4                                                   2                                                              79
  19     83         M     No neoplasia      Pb                  Screening                         US                                                     --                           3.4           \<2.0           Mild stenosis               10--20                    Moderate                               2                                                   2                                                              62

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CT, computed tomography; ERP, endoscopic retrograde pancreatography; IN, intraepithelial neoplasm; LFTs, liver function tests; MPD, main pancreatic duct; MRI, magnetic resonance imaging; Pb, pancreatic body; Ph, pancreatic head; PJC, pancreatic juice cytology; Pt, pancreatic tail; US, ultrasound.

1-absence of abnormal or atypical cells, 2-atypical cells but no evidence of malignancy, 3b-cytology suggestive of, but not conclusive for malignancy, 4-cytology strongly suggestive of malignancy, 5-cytology conclusive for malignancy.

###### 

Characteristics of the Patients Who Were Diagnosed with Malignant Main Pancreatic Duct Stenosis Based on Evaluation of the Resected Specimen

  Case   Surgical procedure   Final diagnosis   Interval between ERP and surgery (mo)   Histological type   Size of invasive region (mm)   Final UICC stage   Chemotherapy after surgery   Follow-up period after surgery (mo)   Survival   Recurrence
  ------ -------------------- ----------------- --------------------------------------- ------------------- ------------------------------ ------------------ ---------------------------- ------------------------------------- ---------- ----------------------------------------
  1      DP                   IN                14                                      HG-PanIN            \-                             0                  No                           21                                    Alive      No
  2      DP                   IN                \<3                                     HG-PanIN            \-                             0                  No                           6                                     Alive      No
  3      DP                   IN                \<3                                     HG-PanIN            \-                             0                  No                           3                                     Alive      No
  4      DP                   Invasive cancer   42                                      Mod                 8                              IA                 No                           18                                    Alive      Recurrence
  5      PD                   Invasive cancer   5                                       Mod                 7                              IIB                S-1                          9                                     Alive      No
  6      DP                   Invasive cancer   \<3                                     Mod                 6                              IB                 Gemcitabine                  68                                    Alive      No with metachronous pancreatic cancer
  7      PD                   Invasive cancer   \<3                                     Wel                 20                             IA                 No                           9                                     Alive      No
  8      DP                   Invasive cancer   \<3                                     Wel                 6                              IB                 S-1                          6                                     Alive      No
  9      PD                   Invasive cancer   \<3                                     Mod                 29                             IIB                No                           2                                     Alive      No

DP, distal pancreatectomy; ERP, endoscopic retrograde pancreatography; HG-PanIN, high-grade pancreatic intraepithelial neoplasia; IN, intraepithelial neoplasm; Mod, moderately differentiated adenocarcinoma; PD, pancreatoduodenectomy; UICC, Union for International Cancer Control Classification; Wel, well differentiated adenocarcinoma.
